Followers | 20 |
Posts | 5522 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Friday, May 01, 2020 6:42:32 PM
Allegedly Biosante completed the pre-marketing phase of the safety trial in December 2012. 3656 patient with an average of 2 years exposure over 7300 patient years as of September 2012. .
Biosante never disclosed the fact that restoring Testosterone (Libigel) reduced cardiovascular events breast cancer events by at least 70%. This information was only learned by reading through patent applications. It would have been disclosed two months after Biosante announced the merger proposal with ANIP. which put as top to the analysis and announcing the discovery. This was under Simes watch as CEO.
December 19, 2015 the patent lawyers added the claim that restoring testosterone reduced breast cancer as well. This information was never disclosed to shareholders or the public. And numerous request to specify how they came to make this claim went unanswered. This is under Art's watch.
If you look at the patent application filed on behalf ANIP, you will see that there is no information supporting the breast cancer reduction claim. By comparison there is much information supporting the the cardiovascular event reduction claims (inlcuding the definition of Cardiovascular events, number of patient years and percentage in reduction of events) None of that is articulated for breast cancer reduction.. Why withhold this information.
My belief is that the breast cancer benefit did not materialize until later in the trial way beyond the alleged conclusion of the first phase of the trial. According to the an American Heart Journal Article the trial was set up as such:
It is likely a partner such as AbbVie which had hired Dr Michael Snabes as their Sr. Medical Director of Men and Women's Health in April 2013. From January to March 2013 he worked for both Biosante and AbbVie simultaneously. He was the study director of the Libigel trials and listed as an inventor in the patent applications claiming to testosterone restoration reduces cardiovascular events and breast cancer.
September 2, 2019 a Global Consensus Position Statement on the Use of Testosterone Therapy for Women was issued. which support restoring Testosterone to treat HSDD
Endorsed by 11 organizations/ societies.
ANIP just authorization got a 10 year extension on keeping protected information in Libigel licence agreement confidential. All previous extensions were 5 years or less.
Anyone partnering with ANIP gets a 5 year head start as they have the safety data which the FDA requires. There is a possibility that once the AbbVie/Allergan is approved and they are integrated you will see them make an FDA application for Intrinsa which proved efficacy but required more safety data, but in a smaller patch form which has patent protection to the Mid 2030's and proved non-inferiority over Intrinsa in a clinical trial. They will use the Libigel trial data to prove testosterone is safety If they go that route look for them to conduct phase 4 trials to address the other indications listed in the Consensus statement (e.g., Cardiovascular (Diabtetes, Hypertenison, etc..) and Breast Cancer event reduction, reduction in bone fractures, improved cognitive function)
Corti appears to be a minor set back which according to Art should be easily addressed.
As for Art, we don't know what caused his sudden departure and all of us are just speculating. We should find out more May 7th. hopefully they will announce his replacement.
JMHO
Recent ANIP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:50:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 01:13:56 PM
- ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 12:53:27 PM
- ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:23:15 PM
- ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution • GlobeNewswire Inc. • 09/13/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • GlobeNewswire Inc. • 09/11/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • Business Wire • 09/11/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:44:38 PM
- ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/10/2024 06:09:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 12:29:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:21:44 PM
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes • GlobeNewswire Inc. • 08/13/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:51:52 AM
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/08/2024 01:44:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:26:24 AM
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/07/2024 11:00:55 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 10:57:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 10:53:07 AM
- ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance • GlobeNewswire Inc. • 08/06/2024 10:50:00 AM
- ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:27:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 09:12:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:07:47 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM